A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 3, 2009, Pages 391-401

  Woodahl, Erica L ^a,b,d   Wang, Joanne ^a,b   Heimfeld, Shelly ^a   Sandmaier, Brenda M ^a,c   O'Donnell, Paul V ^a,c   Phillips, Brian ^a   Risler, Linda ^a   Blough, David K ^a,b   McCune, Jeannine S ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MONTANA   (United States)

Author keywords

Chronic lymphocytic leukemia; Fludarabine; Hematopoietic cell transplantation; Nucleoside transporters; T lymphocytes

Indexed keywords

FLUDARABINE PHOSPHATE; FLUDARABINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; FLUDARABINE; VIDARABINE;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD SAMPLING; CANCER CELL CULTURE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONDITIONING; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG SENSITIVITY; DRUG UPTAKE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METABOLISM; MIDDLE AGED; T LYMPHOCYTE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, LIQUID; FEMALE; GENE EXPRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PHENOTYPE; T-LYMPHOCYTES; VIDARABINE;

EID: 58249128635     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0748-0     Document Type: Article

References (37)

1. JJ Auletta HM Lazarus 2005 Immune restoration following hematopoietic stem cell transplantation: an evolving target Bone Marrow Transplant 35 835 857 (Pubitemid 40667627)
2. F Baron MB Maris BM Sandmaier BE Storer M Sorror R Diaconescu AE Woolfrey TR Chauncey ME Flowers M Mielcarek DG Maloney R Storb 2005 Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning J Clin Oncol 23 1993 2003 (Pubitemid 46211379)
3. F Baron MB Maris BE Storer BM Sandmaier MJ Stuart PA [tmp] McSweeney JP Radich MA Pulsipher ED Agura TR Chauncey DG Maloney JA Shizuru R Storb 2005 HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia Biol Blood Marrow Transplant 11 272 279 (Pubitemid 40450754)
4. F Baron BM Sandmaier 2006 Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning Leukemia 20 1690 1700 (Pubitemid 44590958)
5. F Baron R Storb 2006 Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders Mol Ther 13 26 41 (Pubitemid 41763480)
6. M Barrachina E Castano I Ferrer 2006 TaqMan PCR assay in the control of RNA normalization in human post-mortem brain tissue Neurochem Int 49 276 284 (Pubitemid 43996868)
7. M Bornhauser B Storer JT Slattery FR Appelbaum HJ Deeg J Hansen PJ Martin GB [tmp] McDonald WG Nichols J Radich A Woolfrey A Jenke E Schleyer C Thiede G Ehninger C Anasetti 2003 Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells Blood 102 820 826 (Pubitemid 36917770)
8. R Champlin I Khouri P Anderlini M De Lima C Hosing J [tmp] McMannis J Molldrem N Ueno S Giralt 2003 Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications Oncology (Williston Park) 17 94 100 Discussion 103-107
9. U Consoli I El-Tounsi A Sandoval V Snell HD Kleine W Brown JR Robinson F DiRaimondo W Plunkett M Andreeff 1998 Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia Blood 91 1742 1748 (Pubitemid 28110340)
10. HJ Deeg MB Maris BL Scott EH Warren 2006 Optimization of allogeneic transplant conditioning: not the time for dogma Leukemia 20 1701 1705 (Pubitemid 44590959)
11. ME Dudley JR Wunderlich JC Yang RM Sherry SL Topalian NP Restifo RE Royal U Kammula DE White SA Mavroukakis LJ Rogers GJ Gracia SA Jones DP Mangiameli MM Pelletier J Gea-Banacloche MR Robinson DM Berman AC Filie A Abati SA Rosenberg 2005 Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma J Clin Oncol 23 2346 2357 (Pubitemid 46218728)
12. CM Galmarini X Thomas F Calvo P Rousselot AE Jafaari E Cros C Dumontet 2002 Potential mechanisms of resistance to cytarabine in AML patients Leuk Res 26 621 629 (Pubitemid 34465699)
13. R Gamberale CM Galmarini P Fernandez-Calotti L Jordheim J Sanchez-Avalos C Dumontet J Geffner M Giordano 2003 In vitro susceptibility of CD4+ and CD8+ T cell subsets to fludarabine Biochem Pharmacol 66 2185 2191
14. V Gandhi A Kemena MJ Keating W Plunkett 1993 Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy Leuk Lymphoma 10 49 56 (Pubitemid 23239858)
15. V Gandhi W Plunkett 2002 Cellular and clinical pharmacology of fludarabine Clin Pharmacokinet 41 93 103 (Pubitemid 34264036)
16. E Giovannetti V Mey S Nannizzi G Pasqualetti L Marini M Del Tacca R Danesi 2005 Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells Mol Pharmacol 68 110 118 (Pubitemid 41002949)
17. S Giralt E Estey M Albitar K van Besien G Rondon P Anderlini S O'Brien I Khouri J Gajewski R Mehra D Claxton B Andersson M Beran D Przepiorka C Koller S Kornblau M Korbling M Keating H Kantarjian R Champlin 1997 Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy Blood 89 4531 4536 (Pubitemid 27260263)
18. S Giralt B Logan D Rizzo MJ Zhang K Ballen C Emmanouilides R Nath P Parker D Porter B Sandmaier EK Waller J Barker S Pavletic D Weisdorf 2007 Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program Biol Blood Marrow Transplant 13 844 852 (Pubitemid 46902440)
19. TF Kalhorn AG Ren JT Slattery JS [tmp] McCune J Wang 2005 A highly sensitive high-performance liquid chromatography-mass spectrometry method for quantification of fludarabine triphosphate in leukemic cells J Chromatogr B Analyt Technol Biomed Life Sci 820 243 250 (Pubitemid 40724591)
20. MJ Keating S O'Brien S Lerner C Koller M Beran LE Robertson EJ Freireich E Estey H Kantarjian 1998 Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy Blood 92 1165 1171 (Pubitemid 28369029)
21. IF Khouri M Keating M Korbling D Przepiorka P Anderlini S O'Brien S Giralt C Ippoliti B von Wolff J Gajewski M Donato D Claxton N Ueno B Andersson A Gee R Champlin 1998 Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies J Clin Oncol 16 2817 2824 (Pubitemid 28363047)
22. Landau H, Lamanna N, Hobart S, Weiss MA (2006) High level T cell suppression following purine analog therapy for patients with CLL correlates with important clinical benefit. American Society of Hematology, Orlando, abstract #2784
23. K Lotfi K Karlsson A Fyrberg G Juliusson V Jonsson C Peterson S Eriksson F Albertioni 2006 The pattern of deoxycytidine- and deoxyguanosine kinase activity in relation to messenger RNA expression in blood cells from untreated patients with B-cell chronic lymphocytic leukemia Biochem Pharmacol 71 882 890 (Pubitemid 43208845)
24. JR Mackey CM Galmarini KA Graham AA Joy A Delmer L Dabbagh D Glubrecht LD Jewell R Lai T Lang J Hanson JD Young H Merle-Beral JL Binet CE Cass C Dumontet 2005 Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations Blood 105 767 774 (Pubitemid 40070764)
25. E Mansson T Spasokoukotskaja J Sallstrom S Eriksson F Albertioni 1999 Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line Cancer Res 59 5956 5963 (Pubitemid 30004957)
26. M Maris M Boeckh B Storer M Dawson K White M Keng B Sandmaier D Maloney R Storb J Storek 2003 Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning Exp Hematol 31 941 952 (Pubitemid 37211379)
27. MB Maris D Niederwieser BM Sandmaier B Storer M Stuart D Maloney E Petersdorf P [tmp] McSweeney M Pulsipher A Woolfrey T Chauncey E Agura S Heimfeld J Slattery U Hegenbart C Anasetti K Blume R Storb 2003 HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies Blood 102 2021 2030 (Pubitemid 37122375)
28. PA [tmp] McSweeney D Niederwieser JA Shizuru BM Sandmaier AJ Molina DG Maloney TR Chauncey TA Gooley U Hegenbart RA Nash J Radich JL Wagner S Minor FR Appelbaum WI Bensinger E Bryant ME Flowers GE Georges FC Grumet HP Kiem B Torok-Storb C Yu KG Blume RF Storb 2001 Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects Blood 97 3390 3400
29. M Molina-Arcas B Bellosillo FJ Casado E Montserrat J Gil D Colomer M Pastor-Anglada 2003 Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia Blood 101 2328 2334 (Pubitemid 36304669)
30. M Molina-Arcas S Marce N Villamor I Huber-Ruano FJ Casado B Bellosillo E Montserrat J Gil D Colomer M Pastor-Anglada 2005 Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells Leukemia 19 64 68 (Pubitemid 40090078)
31. D Montagna F Locatelli A Moretta D Lisini C Previdere P Grignani P DeStefano G Giorgiani E Montini S Pagani P Comoli R Maccario 2004 T lymphocytes of recipient origin may contribute to the recovery of specific immune response toward viruses and fungi in children undergoing cord blood transplantation Blood 103 4322 4329 (Pubitemid 38685380)
32. W Plunkett PP Saunders 1991 Metabolism and action of purine nucleoside analogs Pharmacol Ther 49 239 268
33. L Seymour E Eisenhauer 2001 A review of dose-limiting events in phase I trials: antimetabolites show unpredictable relationships between dose and toxicity Cancer Chemother Pharmacol 47 2 10 (Pubitemid 32664505)
34. S Slavin A Nagler E Naparstek Y Kapelushnik M Aker G Cividalli G Varadi M Kirschbaum A Ackerstein S Samuel A Amar C Brautbar O Ben-Tal A Eldor R Or 1998 Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 91 756 763 (Pubitemid 28078275)
35. TR Spitzer S [tmp] McAfee R Sackstein C Colby HC Toh P Multani S Saidman DW Weyouth F Preffer C Poliquin A Foley B Cox D Andrews DH Sachs M Sykes 2000 Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies Biol Blood Marrow Transplant 6 309 320
36. RW Stam ML den Boer JP Meijerink ME Ebus GJ Peters P Noordhuis GE Janka-Schaub SA Armstrong SJ Korsmeyer R Pieters 2003 Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia Blood 101 1270 1276 (Pubitemid 36182495)
37. R Storb 2002 Mixed allogeneic chimerism and graft-versus-leukemia effects in acute myeloid leukemia Leukemia 16 753 754 (Pubitemid 34449763)